Mantle Cell Lymphoma Articles | Page 3

Bendamustine Plus Rituximab Maintains Frontline PFS Benefit in MCL, iNHL After 5 Years
Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.
Ibrutinib Associated With Superior QoL in MCL Compared With Temsirolimus
Phase III results from the RAY trial showed that patients with mantle cell lymphoma treated with ibrutinib (Imbruvica) had superior quality of life compared with patients treated with temsirolimus. 
TP53 Mutations Have Independent Prognostic Value in MCL
Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.
Combination of Ibrutinib and Buparlisib Shows Promise in MCL and other NHLs
Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.
Ibrutinib-Resistant Patients a Core Challenge in MCL
Bijal D. Shah, MD, discusses the current treatment paradigm of MCL, what therapies are moving through the pipeline at a rapid rate, the potential benefit with CAR T-cell therapy, and pivotal biomarker studies currently being conducted.
5-Year Follow-Up Confirms Efficacy of Frontline Bendamustine Plus Rituximab in MCL, iNHL
Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.
Expert Discusses Ibrutinib/Venetoclax Combo in MCL
Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.
Expert  Explains Evolution of MCL Treatment
Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.
Expert Looks to Genetic Testing for Next Leap in MCL
Grzegorz S. Nowakowski, MD, discusses ongoing efforts to determine prognostic factors of mantle cell lymphoma and what other challenges lie ahead.
Intriguing Immunotherapy Regimens Investigated in MCL
Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.
Publication Bottom Border
Border Publication